Skip to main content

Table 1 Baseline characteristics of study patients considered as a whole and by achievement of ID

From: A prediction rule for lack of achievement of inactive disease with methotrexate as the sole disease-modifying antirheumatic therapy in juvenile idiopathic arthritis

FeaturesAll patients (n = 375)Patients who did not achieve ID (n = 146)Patients who achieved ID (n = 229)P#
Gender   0.0004
 Female299 (79.7)103 (70.5)195 (85.6) 
 Male76 (20.3)43 (29.5)33 (14.4) 
Median (IQR) age at disease onset, yrs3.2 (1.7–7.0)4.4 (1.9–8.2)2.7 (1.7–5.5)0.002
Median (IQR) age, yrs5.6 (3.0–9.5)6.3 (3.3–9.9)4.9 (2.8–9)0.05
Median (IQR) disease duration, yrs0.8 (0.4–2.4)0.8 (0.3–2.5)0.9 (0.4–2.4)0.08
Median (IQR) follow-up time, yrs1.5 (0.8–2.5)1.2 (0.5–2.6)1.7 (1–2.5)0.002
Functional phenotypes§   < 0.0001
 Systemic arthritis29/373 (7.8)25 (17.2)4 (1.8) 
 Polyarthritis151/373 (40.5)59 (40.7)92 (40.3) 
 Oligoarthritis174/373 (46.6)49 (33.8)125 (54.8) 
 Enthesitis-related arthritis19/373 (5.1)12 (8.3)7 (3.1) 
Patients with positive ANA264/371 (71.2)79/133 (59.4)185/226 (81.9)< 0.0001
Median (IQR) no. of active joints5 (3–8)5 (3–10)5 (3–7)0.51
Median (IQR) ESR, mm/h (n = 313)40 (21–58)46 (24–62)35.5 (19–56)0.02
Median (IQR) CRP, mg/dl (n = 315)1.3 (0.5–3.6)2 (0.5–4.4)0.9 (0.5–3)0.001
  1. ID inactive disease, IQR interquartile range, ANA antinuclear antibodies, ESR erythrocyte sedimentation rate, CRP C reactive protein
  2. #P value refers to the comparison between patients who did not achieve or achieved ID. §For the purposes of the study analyses, the ILAR categories of juvenile idiopathic arthritis were grouped in functional phenotypes according to Beukelman et al. (ref. [26])
  3. Data are the number (%) unless otherwise indicated